Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

ESMO 2019

27 Sep - 1 Oct 2019

Published: 29 Sep 2019

Views: 2489

Rating:

Save

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Prof Peter Schmid presents data from the KEYNOTE-522 trial during a press conference at the 2019 ESMO congress.

This was a phase III trial looking at immunotherapy added to chemotherapy in early triple negative breast cancer.

Watch Prof Schmid's interview with ecancer here.

Read more about the study here.

Related Videos

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )

Post neoadjuvant management in BRCA mutant breast cancer patients

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Post neoadjuvant management in BRCA mutant breast cancer patients ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

More from ecancer